转移性乳腺癌疗效评估:RECIST 1.1 与 PERCIST 的可行性与一致性
回顾性队列研究纳入 51 例转移性乳腺癌患者、共 151 对 CT 与 FDG-PET 检查,比较 RECIST 1.1 与 PERCIST 的疗效评估适用性。结果发现所有 FDG-PET 检查均有可测量靶病灶,而 65% 的 CT 检查缺乏 RECIST 1.1 可测量靶病灶。FDG-PET 比 CT 更早检出进展,并在 23% 的 CT 寡转移病例中显示更高的转移负荷。
要点
- CT 判定为寡转移的病例中,23% 在 FDG-PET 上显示更高转移负荷。
- FDG-PET 检出进展的时间显著早于 CT(p < 0.05)。
核心结论
- FDG-PET 按 PERCIST 标准在所有转移性乳腺癌病例中均可完成疗效评估,而 CT 按 RECIST 1.1 标准在多数病例中缺乏可测量靶病灶。
- FDG-PET 显示的转移负荷高于 CT,对寡转移的判定有重要影响。
- 整合 FDG-PET 可能优化治疗个体化、扩大临床试验入组资格并支持临床决策,但需进一步验证。
研究设计与样本
- 回顾性队列研究,纳入 2017 至 2025 年间接受系统性治疗的转移性乳腺癌患者。
- 来自大型影像数据库,共 51 例患者、375 次影像检查,形成 151 对 CT 与 FDG-PET 配对检查。
- CT 按 RECIST 1.1 标准分析,FDG-PET 按 PERCIST 标准分析。
- 比较内容包括靶病灶可及性、疗效分类一致性、转移模式(含寡转移)一致性及至进展时间。
关键影像表现/征象
- 151 次 CT 检查中 98 次(65%)缺乏 RECIST 1.1 可测量靶病灶。
- 在 CT 判定为寡转移的病例中,23% 的 FDG-PET 显示更高的转移负荷(p < 0.001)。
诊断标准与关键数值
- 在同时可被 RECIST 1.1 与 PERCIST 评估的 78 对检查中,疗效分类一致率为 68%(53/78)。
- FDG-PET 检出进展的时间显著早于 CT(p < 0.05)。
临床应用与阅片要点
- 转移性乳腺癌行 CT 评估时,多数病例缺乏 RECIST 1.1 可测量靶病灶,需警惕评估失败的可能。
- FDG-PET 能更早提示疾病进展,报告时应注明与 CT 的时间差异。
- CT 判定为寡转移的病例应谨慎,建议结合 FDG-PET 明确真实转移负荷。
- 对拟行局部治疗(如寡转移放疗)的患者,FDG-PET 有助于排除更高的隐匿性转移负荷。
局限性
- 回顾性研究设计,来自单一大型影像数据库,存在选择偏倚可能。
- 原文指出相关发现仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Accurate response assessment during systemic therapy of metastatic breast cancer (mBC) is essential to guide treatment decisions. We aimed to compare the applicability of RECIST 1.1 (CT) and PERCIST (FDG-PET) for response evaluation in mBC within a contemporary real-world setting.
METHODS: In this retrospective cohort study, mBC patients undergoing systemic therapy between 2017 and 2025 were identified from a large imaging database. Paired CT and FDG-PET examinations were analyzed using RECIST 1.1 and PERCIST, respectively. We evaluated target lesion availability, agreement in response categorization, concordance of metastatic patterns-including oligometastatic disease-and time to progression.
RESULTS: Fifty-one patients with 375 imaging examinations were included, yielding 151 paired CT and FDG-PET scans. All FDG-PET scans (151/151) had measurable target lesions according to PERCIST, whereas 65% of CT scans (98/151) lacked measurable target lesions per RECIST 1.1. Response category agreement reached 68% (53/78) among paired scans evaluable by both RECIST 1.1 and PERCIST. FDG-PET detected progression significantly earlier than CT (p < 0.05). In 23% of CT scans classified as oligometastatic, FDG‑PET demonstrated a higher metastatic burden (p < 0.001).
CONCLUSION: In this real-world study of mBC, FDG-PET consistently enabled response assessment according to PERCIST, whereas CT frequently could not provide measurable target lesions according to RECIST 1.1. Moreover, FDG-PET revealed a higher metastatic burden than CT, with implications for classification of oligometastatic disease. These findings suggest that integrating FDG-PET could refine treatment individualization, potentially broaden trial eligibility, and better support clinical decision-making, though further validation is needed.
引用
- Andersson, Johnson, Skarping, et al. RECIST 1.1 and PERCIST for response assessment in metastatic breast cancer: feasibility and agreement in a real‑world retrospective cohort study. Eur J Radiol. 2026. PMID: 42537342. doi:10.1016/j.ejrad.2026.113083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。